Table 1 Model input parameters with uncertainty ranges in brackets
From: Cost-effectiveness of a reactive oral cholera immunization campaign using Shanchol™ in Malawi
| Central | Uncertainty | Source of data | Assumptions | |
|---|---|---|---|---|
| Parameters | value | range | Central value | Uncertainty ranges (min – max) |
| Economic data | ||||
| Vaccine purchase price per fully immunized, 2016 US$ | 3.7 | – | Derived from the analysis | – |
| Vaccine delivery cost per fully immunized, 2016 US$ | 3.6 | [1.1–3.6] | Ilboudo et al. 2017 [14] | (Mogasale et al. 2016 [27]—Ilboudo et al. 2017 [14] |
| Cost of cholera to patients and households, 2016 US$ | 65.6 | [43.0–134.0] | Ilboudo et al. 2017 [15] | (Schaetti et al. 2012 [29]—Poulos et al. 2012 [28] |
| Cost of cholera to health facilities, 2016 US$ | 59.7 | [30.0–61.0] | Ilboudo et al. 2017 [15] | (Poulos et al. 2012 [28]—Schaetti et al. 2012 [29] |
| GDP per capita, 2016 US$ | 372.0 | – | World Bank 2017 [31] | – |
| Discount rate (%) | 3.0 | [1.0–5.0] | WHO 2008 [30] | (Min and max from WHO, 2008 [30]) |
| Epidemiological data | ||||
| Cholera incidence (Inc, cases per 1,000) | 4.0 | [3.0–5.0] | Sauvageot et al. 2017 [32] | (Min and max from Sauvageot et al. 2017 [32]) |
| Case fatality rate (CFR, %) | 2.6 | [1.4–6.7] | M’Bangombé, 2017 [33] | (Min and max from M’Bangombé, 2017 [33]) |
| Vaccine protective duration (Dur, years) | 5.0 | [3.0–5.0] | Bhattacharya et al. 2013 [9] | (Min and max from Bhattacharya et al. 2013 [9]) |
| Length of illness (Length, days) | 5.0 | [4.0–7.0] | Ilboudo et al. 2017 [15] | (Poulos et al. 2012 [28]—Schaetti et al. 2012 [29]) |
| DALY weight (DALY weight) | 0.2 | [0.1–0.3] | Salomon et al. 2012 [36] | (Min and max from Salomon et al. 2012 [36]) |
| Vaccine Efficacy (VEff, no indirect protection) | 58.0 | [42.0–69.0] | Bi et al. 2017 [35] | (Min and max from Bi et al. 2017 [35]) |
| Vaccine Efficacy (VEff, with indirect protection) | 93.0 | [82.0–99.0] | Longini et al. 2007 [24] | (Min and max from Longini et al. 2007 [24]) |
| Campaign coverage rate (%, without indirect protection) | 58.0 | [53.0–91.0] | MSF 2016 [4] | (Min and max from MSF, 2016 [34]) |
| Demographic | ||||
| Population | 90 000.0 | – | – | – |
| Life expectancy at infection (LExp, years) | 58.0 | [50.0–60.0] | WHO, 2016 [37] | (Min and Max from WHO, 2016 [37]) |